K-Cit Oral Solution is a pharmaceutical preparation containing Citric Acid (334 mg/5 ml) and Potassium Citrate (1100 mg/5 ml), formulated to manage metabolic acidosis and prevent kidney stone formation. The combination of citric acid and potassium citrate acts as an alkalinizing agent, increasing urinary pH and citrate levels, thereby reducing the risk of calcium stone crystallization. K-Cit is indicated for patients with conditions such as renal tubular acidosis, hypokalemia, or recurrent calcium nephrolithiasis. The oral solution allows for precise dosing and rapid absorption, facilitating effective correction of systemic acid-base imbalances. Administration should be guided by serum electrolyte and acid-base status, with careful monitoring to avoid hyperkalemia or alkalosis. Contraindications include hyperkalemia, severe renal impairment, and hypersensitivity to any component. Adverse effects may include gastrointestinal disturbances such as nausea, vomiting, or abdominal discomfort. K-Cit Oral Solution is typically administered multiple times daily, with dosage individualized based on clinical response and laboratory parameters. It is essential to maintain adequate hydration during therapy to optimize urinary dilution and minimize stone formation risk. This medication should be used under medical supervision, with periodic evaluation to ensure therapeutic efficacy and safety.